CSL (OTCMKTS:CSLLY) Shares Gap Up – Should You Buy?

CSL Limited Sponsored ADR (OTCMKTS:CSLLY)’s stock price gapped up before the market opened on Friday . The stock had previously closed at $16.35, but opened at $17.2201. CSL shares last traded at $17.30, with a volume of 5,300 shares traded.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Citigroup lowered CSL from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 11th. Royal Bank Of Canada lowered CSL from a “moderate buy” rating to a “hold” rating in a research note on Wednesday, February 11th. Jefferies Financial Group lowered CSL from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 29th. Canaccord Genuity Group lowered CSL from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 11th. Finally, Zacks Research lowered CSL from a “hold” rating to a “strong sell” rating in a research note on Monday, May 11th. Four investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, CSL has a consensus rating of “Reduce”.

CSL Stock Up 3.7%

The business has a 50 day simple moving average of $21.43 and a two-hundred day simple moving average of $41.53. The company has a current ratio of 2.57, a quick ratio of 1.15 and a debt-to-equity ratio of 0.51.

About CSL

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.